TRI-ESTARYLLA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-ESTARYLLA (TRI-ESTARYLLA).
Combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone is a spironolactone analogue with anti-mineralocorticoid and antiandrogenic activity, also suppressing ovulation and increasing cervical mucus viscosity.
| Metabolism | Primarily via CYP3A4; ethinyl estradiol also undergoes sulfation. Drospirenone is metabolized via CYP3A4 and to a minor extent via reduction and subsequent glucuronidation. |
| Excretion | Renal: approximately 60% as unchanged drug and metabolites; Biliary/fecal: approximately 40%, primarily as metabolites. |
| Half-life | Terminal elimination half-life is 4-6 hours; clinical context: allows twice-daily dosing for stable blood levels. |
| Protein binding | Approximately 70-80% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.5-0.7 L/kg; clinical meaning: moderate distribution into total body water, with limited tissue penetration. |
| Bioavailability | Oral: approximately 90% due to minimal first-pass metabolism. |
| Onset of Action | Oral: 1-2 hours for initial therapeutic effect; peak effect at 3-5 hours. |
| Duration of Action | Oral: 8-12 hours; clinical note: sustained effect due to active metabolites, supporting twice-daily dosing. |
| Molecular Weight | Ethinylestradiol: 296.4 g/mol; Norgestimate: 369.5 g/mol |
One tablet (ethinyl estradiol 0.03 mg / norgestimate 0.18-0.215-0.25 mg) orally once daily for 21 days followed by 7 placebo days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required in mild-to-moderate renal impairment; contraindicated in severe renal disease due to potential fluid retention and hyperkalemia. |
| Liver impairment | Contraindicated in Child-Pugh class C (severe hepatic impairment); use with caution in Child-Pugh class A or B, with monitoring for signs of hepatotoxicity. |
| Pediatric use | Post-menarche only: same as adult dosing (one tablet daily); not indicated for pre-menarche use. |
| Geriatric use | Not indicated for postmenopausal use; higher risk of thromboembolism and cardiovascular events in women over 35 who smoke; consider non-hormonal contraceptives. |
| 1st trimester | Risk of masculinization of female fetus if used during the critical period of sexual differentiation (8-10 weeks gestation). Some data suggest increased risk of hypospadias with first trimester exposure. Use is contraindicated. |
| 2nd trimester | Risk of virilization of female fetus continues; may cause hepatic dysfunction. Use is contraindicated. |
| 3rd trimester | Risk of virilization of female fetus persists; potential for hepatic adverse effects. Use is contraindicated. |
Clinical note
Comprehensive clinical and safety monograph for TRI-ESTARYLLA (TRI-ESTARYLLA).
| Placental transfer | Ethinylestradiol and norgestimate/levonorgestrel cross the placenta; fetal exposure is significant. |
| Breastfeeding | Excreted into human milk; may cause adverse effects in nursing infants, including virilization and hepatic dysfunction. Use is contraindicated during breastfeeding. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
| Serious Effects |
Known or suspected pregnancyHistory of or current thrombophlebitis or thromboembolic disordersCerebrovascular or coronary artery diseaseKnown or suspected breast carcinomaUndiagnosed abnormal genital bleedingKnown or suspected estrogen-dependent neoplasiaHepatic adenoma or carcinomaActive liver diseaseCholestatic jaundice of pregnancy or jaundice with prior hormonal useHypersensitivity to any component
| Precautions | Thrombotic disorders (including venous thromboembolism and arterial thromboembolism), Liver disease (including hepatic adenoma, liver tumors), Hypertension, Gallbladder disease, Carbohydrate and lipid metabolism effects, Headache/migraine, Menstrual irregularities and amenorrhea, Depression, Cervical cancer, Hereditary angioedema, Chloasma, Hepatitis C treatment interaction with ombitasvir/paritaprevir/ritonavir and dasabuvir |
| Food/Dietary |
Loading safety data…
| Lactation Rating | Avoid |
| Teratogenic Risk | First trimester: Use not recommended due to risk of cardiovascular and neural tube defects. Second and third trimesters: Fetal exposure to estrogens and progestins may cause genitourinary tract abnormalities, but risk is low. Overall: Pregnancy contraindicated. |
| Fetal Monitoring | Monitor blood pressure, weight, and signs of thromboembolism. Inadvertent use during pregnancy: fetal ultrasound for anomalies. |
| Fertility Effects | Suppresses ovulation as contraceptive effect. After discontinuation, fertility returns to baseline. No permanent impairment. |
| No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Avoid excessive alcohol consumption as it may impair liver function. The pill can be taken with or without food. Taking with food may reduce nausea. |
| Clinical Pearls | Tri-Estarylla is a combined oral contraceptive containing ethinyl estradiol and norgestimate. It is a triphasic pill with varying hormone doses throughout the cycle. Use for contraception. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed pill management: if one pill missed, take as soon as remembered; if two or more missed, use backup contraception. May reduce menstrual cramps and acne. Caution in patients with migraine with aura, hypertension, or history of DVT. |
| Patient Advice | Take one pill daily at the same time, preferably after an evening meal to reduce nausea. · If you miss one pill, take it as soon as you remember, even if that means taking two pills in one day. · If you miss two or more pills, use a backup contraceptive method (e.g., condoms) for the next 7 days. · Common side effects include nausea, breast tenderness, breakthrough bleeding, and mood changes; these often improve after 2-3 cycles. · Do not smoke while taking this medication, especially if you are over 35, as it increases risk of blood clots. · Seek medical attention for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, or severe headache. · This medication does not protect against HIV or other sexually transmitted infections. |